A Holistic Approach to the Development of Multi-Targeted Medicines (Using the Example of the Phenylpropanoid Class)

Avdeeva Elena V¹*, Varina Natalia R², Kurkin Vladimir A³, Izmalkov Nikolai S⁴, Ryazanova Tatyana K⁵, Sharafutdinova Anastasia Yu⁶ and Dubishchev Aleksey V⁷

¹Head of the Department of Pharmacology Named After the Honored Scientist of the Russian Federation Professor A.A. Lebedev, Professor, Samara State Medical University, Russian Federation
²Assistant Professor of Department Pharmacognosy with Botany and Fundamentals of Phytotherapy, Samara State Medical University, Russian Federation
³Head of the Department of Pharmacognosy with Botany and Fundamentals of Phytotherapy, Professor, Samara State Medical University, Russian Federation
⁴Chief Physician of the Clinics of SamSMU, Assistant Professor of Department Public Health and Public Health of the Institute of Professional Education, Samara State Medical University, Russian Federation
⁵Director of the Scientific and Educational Center "Pharmacy" of SamSMU, Samara State Medical University, Russian Federation
⁶Chief Specialist, Institute Biotechnological Center «BioTech» Samara State Medical University, Russian Federation
⁷Professor of Department Pharmacology named after the Honored Scientist of the Russian Federation Professor A.A. Lebedev, Samara State Medical University, Russian Federation

*Corresponding Author: Avdeeva Elena V, Head of the Department of Pharmacology Named After the Honored Scientist of the Russian Federation Professor A.A. Lebedev, Professor, Samara State Medical University, Russian Federation.

Received: May 16, 2025; Published: May 26, 2025

Abstract

The article is devoted to the use of a holistic approach for targeted drug development based on the etiopathogenesis of conditions and diseases. The implementation of the approach is discussed using the example of a currently actively studied class of biologically active substances, phenylpropanoids, as having a polytargeting effect. At the same time, the relevance of developing the methodological foundations of a special section of pharmacology - phytopharmacology and the request of practical healthcare for organoprotective drugs is taken into account.

The aim of the study was to substantiate the feasibility of using a holistic approach in the creation of polytargeted medicines and to develop a design for their preclinical and clinical study based on the etiopathogenesis of conditions.

Discussion: The published data show that from the standpoint of evidence-based pharmacy, it is important to have an in-depth knowledge of the chemical composition of raw materials and drug candidate substances; on this basis, to obtain standardized pharmacologically active substances; further, to study their safety and effectiveness for the body as a whole. Thus, for a targeted study of the effects of phenylpropanoids on the nodal links of pathogenesis (and sanogenesis), a corresponding fragment of cause-and-effect relationships in disorders of specific and nonspecific body resistance was constructed. The presented etiopathogenesis architecture determined the content of the conducted preclinical and clinical study of phenylpropanoids and their derivatives. On this basis, and taking into account the data of other researchers, the corresponding architecture of phenylpropanoid pharmacodynamics has been developed. The information that is constantly being updated in the publication data set confirms the correctness of the architectures, which does not exclude their subsequent completion.

Conclusion: When developing drugs, especially if a targeted effect is predicted, it is advisable to base the design of preclinical studies on the architecture of etiopathogenesis, ideally using etiopathogenetic experimental models at different levels of the organization of the living. Then it should be expected that further clinical application will implement the principle: we treat not the disease, but the patient, and taking into account the introduction of artificial intelligence technologies, a complete personification of pharmacocorrection will be achievable.

Keywords: Holism; Holistic Model of Health; Architecture of Etiopathogenesis; Polypharmacology; Phenylpropanoids; Organoprotection

References

1. Nikiforov AL. “Holism. New Philosophical Encyclopedia”. Institute of Philosophy of the Russian Academy of Sciences; National Society-Scientific Foundation; 2^nd, ispr. and add. (2010).
2. “Metaphysics. Works in four volumes”. Book 8, Chapter 6. 1 (1976).
3. Sychev DA., et al. “Phytopharmacology: at the origins of pharmacy and clinical pharmacology”. Pharmacokinetics and Pharmacodynamics 1 (2014): 63-73.
4. Khudyakova NL. “Human being as integrity”. Bulletin of Chelyabinsk State University424 (2019): 35-43.
5. Botkin SP. “The course of the clinic of internal diseases”. Medgiz 1 (1950).
6. Gupta SC., et al. “Therapeutic roles of curcumin: lessons learned from clinical trials”. AAPS Journal 1 (2013): 195-218.
7. Zhang X., et al. “Meta-analysis-based systematic review of effect of traditional Chinese medicine intervention in treatment of diabetic nephropathy on thyroid function”. Annals of Palliative Medicine6 (2021): 6736-6752.
8. Srinivas RA and Shuxing Zh. “Polypharmacology: drug discovery for the future”. Annals of Palliative Medicine1 (2013): 41-47. 
9. Malliori M. “No health without mental health-towards a holistic approach”. Annals of Genetic Psychiatry1 (2010): 35.
10. Majuga AG and Sabekiya RB. “Ontology of health: a holistic approach”. Bulletin of the Bashkir University4 (2013): 1233-1236.
11. Bullington J. “A phenomenological approach to the expression of the psychosomatic body”. Chapter 6. Health, disease and holistic health”. Psychology and Psychotechnics 7 (201): 663-675.
12. Karr JR., et al. “A whole-cell computational model predicts phenotype from genotype”. Cell2 (2012): 89-401.
13. Zheng C., et al. “System-level multi-target drug discovery from natural products with applications to cardiovascular diseases”. Molecular Diversity 3 (2014): 621-635.
14. Hauser AS., et al. “Pharmacogenomics of GPCR Drug Targets”. Cell1-2 (2018): 41-54.
15. Lahoz-Beneytez J., et al. “A pharma perspective on the systems medicine and pharmacology of inflammation”. Mathematical Bioscience 260 (2015): 2-5.
16. , et al. “Phenylpropanoids and its derivatives: biological activities and its role in food, pharmaceutical and cosmetic industries”. Critical Reviews in Food Science and Nutrition 60.16 (2020): 2655-2675.
17. Schaefer CF., et al. “PID: the Pathway Interaction Database”. Nucleic Acids Research1 (2009): 674-679.
18. Kiseleva TL and Kiseleva MA. “Synergistic aspects of modern pharmacotherapy in gastroenterology”. Traditional Medicine57 (2019): 16-31.
19. Pun FW., et al. “AI-powered therapeutic target discovery”. Trends in Pharmacological Science9 (2023): 561-572.
20. Makhoba XH., et al. “Potential impact of the multi-target drug approach in the treatment of some complex Diseases”. Drug Design, Development and Therapy 14 (2020): 3235-3249.
21. Vincent F., et al. “Phenotypic drug discovery: recent successes, lessons learned and new directions”. Nature Reviews Drug Discovery12 (2022): 899-914.
22. Ha J., et al. “Recent advances in identifying protein targets in drug discovery”. Cell Chemical Biology3 (2021): 394-423.
23. Ramsay RR., et al. “A perspective on multi-target drug discovery and design for complex diseases”. Clinical and Translational Medicine 1 (2018): 3.
24. Vasilyev PM, et al. “Polyfunctional multitarget drugs as a basis of pharmacology of the 21st century”. Science Journal of VolSU. Natural Sciences1 (2018): 36-39.
25. Löscher W. “Single-target versus multi-target drugs versus combinations of drugs with multiple targets: preclinical and clinical evidence for the treatment or prevention of epilepsy”. Frontiers in Pharmacology 12 (2021): 730257.
26. Zhixuan H., et al. “Network pharmacology-based prediction and "gut microbiota-inflammation-brain axis" validation of the active ingredients and potential mechanisms of Plantagins Herba for treating diabetes-related cognitive dysfunction”. Frontiers in Pharmacology | Neuropharmacology 16 (2025).
27. Sánchez-Tejeda JF., et al. “A Definition of “multitargeticity”: identifying potential multitarget and selective ligands through a vector analysis”. Frontiers in Chemistry 8 (2020): 176.
28. Hao J., et al. “Editorial: Plant and fungal extracts and metabolites in neurotherapy: exploring their pharmacology and potential clinical uses”. Frontiers in Pharmacology 16 (2025): 1602574.
29. Huang Z., et al. “Traditional Chinese medicine for lupus nephritis: modulation of autoimmune pathogenesis”. Frontiers in Pharmacology 16 (2025): 1523272.
30. Zhanpin Zhu., et al. “Simple phenylpropanoids: recent advances in biological activities, biosynthetic pathways, and microbial production”. Natural Product Reports1 (2024): 6-24
31. Kurkin VA. “Phenуlpropanoids from medicinal plants: distribution, classification, structural analysis, and biological activity”. Chemistry of Natural Compounds 2 (2003): 123-153.
32. Calixto P. da S., et al. “In silico study examining new phenylpropanoids targets with antidepressant activity”. Current Drug Targets5 (2021): 539-554.
33. Shevchuk OM., et al. “Searching for new plant sources rosemary acid”. Bulletin of the State Nikitsky Botanical Gardens 150 (2024): 136-145.
34. Yang N., et al. “Bioactive compound combinations from Rhodiola tangutica alleviate pulmonary vascular remodeling in high-altitude pulmonary hypertension rats through the PI3K-AKT pathway”. Frontiers in Pharmacology 16 (2025): 1582677.
35. Su G., et al. “Phytochemical and pharmacological progress on the genus Syringa”. Chemistry Central Journal2 (2015): 1-12.
36. Burlou-Nagy C., et al. “Echinacea purpurea (L.) Moench: Biological and pharmacological properties. A review”. Plants9 (2022). Art. ID: 1244.
37. Mutz M., et al. “Microbial synthesis of the plant natural product precursor p-coumaric acid with Corynebacterium glutamicum”. Microbial Cell Factories 22 (2023): 209.
38. Zhou X., et al. “Structure-guided engineering of 4-coumarate: CoA ligase for efficient production of rosmarinic acid in Saccharomyces cerevisiae”. Journal of Biotechnology396 (2024): 140-149.
39. Ryazanova TK and Kurkin VA. “The use of reference materials in the analysis of medicinal plant raw materials and herbal medicinal products”. Measurement Standards. Reference Materials2 (2023) 47-60.
40. Sakanyan EI., et al. “Current requirements for the quality of herbal medicinal products”. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya. Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products3 (2018): 170-178.
41. Kovač Z. “Pathophysiological body reactivity and interactions in comorbidities. synergism versus antagonism of disease pathways and etiopathogenetic clusters in comorbidity conditions”. Psychiatry Danub4 (2021): 414-426.
42. Hyskova V and Ryslava H. “Antioxidant properties of phenylpropanoids”. Biochemistry and Analytical Biochemistry 3 (2019): е171.
43. Kuznetsov SL., et al. “Obtaining and studying the antioxidant activity and hepatoprotective effect of a polymer composition containing silybin”. Russian nanotechnology1 (2024): 112-120.
44. Kurkin V.A., et al. “Phenylpropanoids as a class of natural biologically active compounds - organoprotectors”. Pharmacy and Pharmacology5 (2023): 399-411.
45. Lopez-Munguıa A., et al. “Phenylpropanoid glycoside analogues: enzymatic synthesis, antioxidant activity and theoretical study of their free radical scavenger mechanism”. PLoS ONE6 (2011): 1-9.
46. , et al. “Phenylpropanoids and its derivatives: biological activities and its role in food, pharmaceutical and cosmetic industries”. Critical Reviews in Food Science and Nutrition 60.16 (2020): 2655-2675.
47. Badekova KJ., et al. “Biological properties of rosmarinic acid”. Farmaciâ Kazahstana8 (2020): 29-34.
48. Kankanige D., et al. “Application of transcriptomics for predicting protein interaction networks, drug targets and drug candidatesЭ”. Frontiers in Medical Technology 4 (2022): 693148.
49. Wishart DS. “Emerging applications of metabolomics in drug discovery and precision medicine”. Nature Reviews in Drug Discovery7 (2016): 473-484.
50. Kell DB and Goodacre R. “Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery”. Drug Discovery Today2 (2014): 171-182.

Citation

Citation: Avdeeva Elena V., et al. “A Holistic Approach to the Development of Multi-Targeted Medicines (Using the Example of the Phenylpropanoid Class)". Acta Scientific Pharmaceutical Sciences 9.5 (2025): 35-46.

Copyright

Copyright: © 2025 Avdeeva Elena V., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.